Melflufen therapy for relapsed refractory multiple myeloma (RRMM) patients refractory to daratumumab and/or pomalidomide: A report on early efficacy

Authors
Category Primary study
JournalBlood
Year 2017
This article has no abstract
Epistemonikos ID: 19d555e1d659e7a3f88f0acc071e3b63c4a40b0f
First added on: Feb 08, 2025